C4 Therapeutics, Inc. (CCCC): Capital Expenditures
$607.0K
Year ended 2025-12-31
$523.0K
Trailing 12 months to 2026-06-30
-52.0%
3-year compound annual growth
-1.4%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $607.0K | +237.2% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $180.0K | -89.5% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $1.71M | -68.9% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $5.50M | +330.4% | 2024-02-22, From 2022-01-01 |
| 2021-12-31 | $1.28M | +96.5% | 2023-02-23, From 2021-01-01 |
| 2020-12-31 | $650.0K | -51.8% | 2022-02-24, From 2020-01-01 |
| 2019-12-31 | $1.35M | n/a | 2022-02-24, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $607.0K | +237.2% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $0 | -100.0% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $85.0K | -66.0% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.45M | -88.7% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $102.0K | -61.8% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $2.60M | -26.3% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $607.0K | -93.1% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $133.0K | n/a |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $574.0K | -81.6% |
Compare CCCC, XFOR, DTIL, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗